These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 2852596)

  • 1. Involvement of beta-endorphin and mu-opioid receptors in mediating the aversive effect of lithium in the rat.
    Shippenberg TS; Millan MJ; Mucha RF; Herz A
    Eur J Pharmacol; 1988 Sep; 154(2):135-44. PubMed ID: 2852596
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of chronic lithium treatment upon the motivational effects of opioids: alteration in the effects of mu- but not kappa-opioid receptor ligands.
    Shippenberg TS; Herz A
    J Pharmacol Exp Ther; 1991 Mar; 256(3):1101-6. PubMed ID: 1848627
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential effects of mu and kappa opioid systems on motivational processes.
    Shippenberg TS; Herz A
    NIDA Res Monogr; 1986; 75():563-66. PubMed ID: 2829003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Involvement of central mu and delta opioid receptors in mediating the reinforcing effects of beta-endorphin in the rat.
    Bals-Kubik R; Shippenberg TS; Herz A
    Eur J Pharmacol; 1990 Jan; 175(1):63-9. PubMed ID: 1969799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Motivational effects of opioids: influence of D-1 versus D-2 receptor antagonists.
    Shippenberg TS; Herz A
    Eur J Pharmacol; 1988 Jul; 151(2):233-42. PubMed ID: 2844553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aversive properties of naloxone in non-dependent (naive) rats may involve blockade of central beta-endorphin.
    Mucha RF; Millan MJ; Herz A
    Psychopharmacology (Berl); 1985; 86(3):281-5. PubMed ID: 2863837
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mu-, delta-, kappa- and epsilon-opioid receptor modulation of the hypothalamic-pituitary-adrenocortical (HPA) axis: subchronic tolerance studies of endogenous opioid peptides.
    Iyengar S; Kim HS; Wood PL
    Brain Res; 1987 Dec; 435(1-2):220-6. PubMed ID: 2892574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Place preference conditioning reveals the involvement of D1-dopamine receptors in the motivational properties of mu- and kappa-opioid agonists.
    Shippenberg TS; Herz A
    Brain Res; 1987 Dec; 436(1):169-72. PubMed ID: 2961413
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beta-endorphin-(1-27) is a naturally occurring antagonist of the reinforcing effects of opioids.
    Bals-Kubik R; Herz A; Shippenberg TS
    Naunyn Schmiedebergs Arch Pharmacol; 1988 Oct; 338(4):392-6. PubMed ID: 2854207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Place-conditioning properties of mu, kappa, and sigma opioid agonists.
    Iwamoto ET
    Alcohol Drug Res; 1985-1986; 6(5):327-39. PubMed ID: 3011025
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glycyl-glutamine, an endogenous beta-endorphin-derived peptide, inhibits morphine-induced conditioned place preference, tolerance, dependence, and withdrawal.
    Cavun S; Göktalay G; Millington WR
    J Pharmacol Exp Ther; 2005 Nov; 315(2):949-58. PubMed ID: 16079299
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tolerance and selective cross-tolerance to the motivational effects of opioids.
    Shippenberg TS; Emmett-Oglesby MW; Ayesta FJ; Herz A
    Psychopharmacology (Berl); 1988; 96(1):110-5. PubMed ID: 3147470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beta-endorphin: a highly selective endogenous opioid agonist for presynaptic mu opioid receptors.
    Schoffelmeer AN; Warden G; Hogenboom F; Mulder AH
    J Pharmacol Exp Ther; 1991 Jul; 258(1):237-42. PubMed ID: 1677039
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endogenous enkephalins, not endorphins, modulate basal hedonic state in mice.
    Skoubis PD; Lam HA; Shoblock J; Narayanan S; Maidment NT
    Eur J Neurosci; 2005 Mar; 21(5):1379-84. PubMed ID: 15813947
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of mu and kappa opioid receptor agonists on rat plasma corticosterone levels.
    Hayes AG; Stewart BR
    Eur J Pharmacol; 1985 Oct; 116(1-2):75-9. PubMed ID: 2996912
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Motivational effects of opioids in an animal model of prolonged inflammatory pain: alteration in the effects of kappa- but not of mu-receptor agonists.
    Shippenberg TS; Stein C; Huber A; Millan MJ; Herz A
    Pain; 1988 Nov; 35(2):179-186. PubMed ID: 2853321
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Morphine-induced place preference in the CXBK mouse: characteristics of mu opioid receptor subtypes.
    Suzuki T; Funada M; Narita M; Misawa M; Nagase H
    Brain Res; 1993 Jan; 602(1):45-52. PubMed ID: 8383571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Opioid receptor subtype involvement in maternal behavior in lactating rats.
    Mann PE; Kinsley CH; Bridges RS
    Neuroendocrinology; 1991 May; 53(5):487-92. PubMed ID: 1651460
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The inhibition of ornithine decarboxylase activity in developing rat tissues by central nervous system beta-endorphin is mediated by mu-opioid receptors, but not by delta- or epsilon-opioid receptors.
    Bartolome JV; Chang KJ; Bartolome MB
    Eur J Pharmacol; 1995 Sep; 284(1-2):43-50. PubMed ID: 8549635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evidence for kappa- and mu-opioid receptor expression in C6 glioma cells.
    Bohn LM; Belcheva MM; Coscia CJ
    J Neurochem; 1998 May; 70(5):1819-25. PubMed ID: 9572265
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.